Print…

Procurou por: Shimadzu+Diagnostics+Europe


59 589  resultados encontrados

SearchResultCount:"59589"

Sort Results

Visualização em Lista Easy View (new)

Classifique os resultados da pesquisa

Código de Artigo: (SIALN0399000)
Fornecedor: Merck
Descrição: NEOHESPERIDIN DIHYDROCHALCONE, EUROP 1 * 1 unid.
UOM: 1 * 1 unid.


Código de Artigo: (SIALP2810000)
Fornecedor: Merck
Descrição: PREDNISOLONE SODIUM PHOSPHATE, EUROP 1 * 1 unid.
UOM: 1 * 1 unid.


Código de Artigo: (SIALM1825000)
Fornecedor: Merck
Descrição: METOCLOPRAMIDE HYDROCHLORIDE, EUROPE 1 * 1 unid.
UOM: 1 * 1 unid.


Código de Artigo: (SIALY0001436)
Fornecedor: Merck
Descrição: MONTELUKAST DICYCLOHEXYLAMINE, EUROP 1 * 1 unid.
UOM: 1 * 1 unid.


Código de Artigo: (SIALC1540000)
Fornecedor: Merck
Descrição: CHLORHEXIDINE DIHYDROCHLORIDE, EUROP 1 * 1 unid.
UOM: 1 * 1 unid.


Código de Artigo: (SIALC3200000)
Fornecedor: Merck
Descrição: CYCLOBENZAPRINE HYDROCHLORIDE, EUROP 1 * 1 unid.
UOM: 1 * 1 unid.


Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Código de Artigo: (SIALY0001727)
Fornecedor: Merck
Descrição: SODIUM ALENDRONATE TRIHYDRATE, EUROP 1 * 1 unid.
UOM: 1 * 1 unid.


Código de Artigo: (STMC100-1394)
Fornecedor: STEMCELL TECHNOLOGIES
Descrição: Stimulating T cells with HPV16 (E7) Peptide pool releases downstream cytokines and upregulates activation markers, enabling antigen-specific T cells to be detected or isolated for analysis. HPV16 (E7) Peptide pool is a lyophilised mixture of 22 peptides from protein E7 of human papillomavirus type 16 (HPV16) consisting of 15-mer peptides with 11-amino-acid overlaps that cover amino acids 1 to 98 on protein E7. E7 is an oncoprotein that binds and mediates degradation of the retinoblastoma tumor suppressor protein pRB (Gonzalez <i>et al.</i>). E7 together with E6 demonstrated the ability to immortalize human keratinocytes in vitro, which likely has significance for HPVs oncogenic potential (Hawley-Nelson <i>et al.</i>). Viral peptide pools are useful for a broad range of applications, including vaccine development, immunological research, and diagnostic assay development.
UOM: 1 * 1 UA

Market Source Item This is a MarketSource item. Additional charges may apply

Código de Artigo: (BNUM1090-50)
Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.
UOM: 1 * 50 µl


Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Fornecedor: Biotium
Descrição: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Código de Artigo: (STMC100-1398)
Fornecedor: STEMCELL TECHNOLOGIES
Descrição: Stimulating T cells with BKV (LT) Peptide pool releases downstream cytokines and upregulates activation markers, enabling antigen-specific T cells to be detected or isolated for analysis. BKV Peptide pool is a lyophilised mixture of 171 peptides from the Large T (LT) antigen of BK polyomavirus (BKV), and consists of 15-mer peptides with 11-amino-acid overlaps that cover amino acids 1 to 695 on LT antigen. LT antigen is an early viral protein (Low <i>et al.</i>) that contributes to the transformation and maintenance of host cells (Nakshatri <i>et al.</i>). It has been found to bind to a subset of tumor suppressor proteins (Harris <i>et al.</i>), and its co-expression with p53 has been observed in polyomavirus-associated nephropathy (Seemayer <i>et al.</i>). Viral peptide pools are useful for a broad range of applications, including vaccine development, immunological research, and diagnostic assay development.
UOM: 1 * 1 UA

Market Source Item This is a MarketSource item. Additional charges may apply

Preço sob consulta
O stock para este item é limitado. Por favor, certifique-se de que efetuou o seu login para visualizar o stock disponível. Se a call ainda é exibida e precisar de ajuda, por favor, ligue para 213 600 770
O stock para este item é limitado. Por favor, certifique-se de que efetuou o seu login para visualizar o stock disponível. Se a call está visível e precisar de ajuda, por favor, ligue para 213 600 770
Este produto é sujeito a regulamentação especifica.
Em caso de encomenda, será contactado a solicitar documentação complementar necessária e/ou obrigatória (licença, autorização ou declaração de uso final) para a continuidade do pedido. Agradecemos a vossa compreensão
Este produto é sujeito a regulamentação especifica.
Em caso de encomenda, será contactado a solicitar documentação complementar necessária e/ou obrigatória (licença, autorização ou declaração de uso final) para a continuidade do pedido. Agradecemos a vossa compreensão.
Este produto está bloqueado. Para obter mais informações, contacte a VWR através do número 213 600 770.
O produto pretendido já não se encontra disponível. O produto indicado é um substituto.
Este produto encontra-se em rutura de stock. Poderá encontrar alternativas pesquisando pelo código de artigo indicado acima. Se precisar de ajuda, por favor contacte a VWR através do 213 600 770.
401 - 416 of 59 589
no targeter for Bottom